It has been shown that pharmacological activation of PTEN, a potent tumor suppressor gene, can dominantly antagonize the proto-oncogenic phosphoinositide 3-kinase (PI3K)–AKT signaling pathway with acceptable side effects (79). This evidence concerns the gene ENSG00000280371 and neoplasm.